The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.
Not Applicable
Recruiting
- Conditions
- Digestive Systemliver cirrhosis
- Registration Number
- PACTR201405000798226
- Lead Sponsor
- ational Liver Institute, Menoufiya University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1-the presence of tense ascites determined by clinical examination and abdominal ultrasound, requiring frequent therapeutic paracentesis
Exclusion Criteria
1-arterial hypertension, history of coronary disease, cardiac failure, respiratory disease.
2-hepatic encephalopathy.
3-sepsis
4-spontaneous bacterial peritonitis (defined by polymorphonuclear cell count >250/mm3 in ascites
5-elevated creatinine concentration >1.5 mg/dL
6-gastrointestinal bleeding within 7 days before the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link paracentesis flow rate to circulatory dysfunction in liver cirrhosis patients?
How does paracentesis flow rate compare to standard-of-care management for ascites in liver cirrhosis?
Are there specific biomarkers that predict risk of paracentesis-induced circulatory dysfunction in cirrhotic patients?
What adverse events are associated with high vs. low flow rate paracentesis in liver cirrhosis and how are they managed?
How do paracentesis flow rate protocols at Menoufiya University compare to other institutions in managing liver cirrhosis ascites?